A Phase 1/2 interventional study of REC-1245 in Unresectable, Locally Advanced and Metastatic Cancers, sponsored by Recursion Pharmaceuticals Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Recursion Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of REC-1245 for the treatment of participants with unresectable locally advanced or metastatic solid tumors. Participants will receive treatment with REC-1245 for up to 2 years.
3,018 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
This study's planned enrollment of 170 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Recursion Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Finding
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Drug: REC-1245
Oral
Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
To characterize the incidence of DLTs
Time frame: Initiation of study drug through 4 weeks
Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event
To characterize the incidence of treatment emergent adverse events
Time frame: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
Phase 2- Objective Response Rate (ORR)
To assess tumor response
Time frame: Initiation from study drug until disease progression (up to approximately 24 months)
Phase 1- ORR
To assess tumor response
Time frame: Initiation from study drug until disease progression (up to approximately 24 months)
Phase 1 and 2- Disease Control Rate (DCR)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 and 2 - Duration of Response (DOR)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 and 2 - Duration of Stable Disease (SD)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 and 2 - Time to Response (TTR)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 and 2 - Progression Free Survival (PFS)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 and 2 - Overall Survival (OS)
To assess the anti-tumor activity
Time frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
Phase 1 - Maximum Plasma Concentration (Cmax)
To characterize PK of REC-1245
Time frame: Initiation of study drug through Week 9
Phase 1 - Time to Reach Maximum Plasma Concentration (Tmax)
To characterize PK of REC-1245
Time frame: Initiation of study drug through Week 9
Phase 1 - Plasma Concentration Before the Next Dose (Ctrough)
To characterize PK of REC-1245
Time frame: Initiation of study drug through Week 9
Phase 1 - Area Under Plasma Concentration-time Curve (AUC)
To characterize PK of REC-1245
Time frame: Initiation of study drug through Week 9
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Recursion Pharmaceuticals Inc.